mercredi 25 novembre 2020

Partenariats public-privés pour la recherche contre le Covid-19


BPI France finance jusqu'à 50 millions d'euros des travaux de recherche et développement qui associent des industriels et leurs partenaires publics, dans le cadre de la lutte contre l'épidémie de Covid-19.

 

Ce programme propose de soutenir des projets collaboratifs de recherche et développement structurants visant le développement de solutions thérapeutiques à visée préventive ou curative contre le COVID-19. Des retombées économiques et technologiques directes sous forme de nouveaux produits, services et technologies, sont attendues. Toutes les stratégies thérapeutiques sont éligibles (vaccinales, antivirales, mixtes, etc.) ainsi que toutes les technologies (chimie, biotechnologie, intelligence artificielle et exploitation de données massives ou dispositif médical si pertinent).

 

Date limite de candidature 01 décembre 2020.
+ d'infos : https://www.bpifrance.fr/A-la-une/Appels-a-projets-concours/PSPC-COVID-19-49161

mercredi 25 novembre 2020

L’ANR soutient les recherches à court terme sur le Covid-19


 

L'Agence nationale de la recherche lance un nouvel appel pour soutenir des projets de type recherche-action RA-Covid-19 dont les résultats pourraient être diffusés à la société dans les trois à douze prochains mois.

Pour assurer sa réactivité, cet appel qui prolonge l'appel Flash Covid-19, sera ouvert en continu jusqu'au 28 octobre 2020

 

Conformément aux recommandations de l'Organisation mondiale de la Santé, les thématiques de l'appel concernent :

  • les études épidémiologiques,
  • la physiopathogénie de la maladie,
  • la prévention et contrôle de l'infection,
  • l'éthique et dynamiques sociales,
  • les enjeux globaux de l'épidémie Covid-19.

Pour permettre un financement rapide des propositions, la sélection sera opérée au fil de l'eau.

 

L'ouverture du site de dépôt des projets est prévue le 20 avril 2020.

 

https://intranet.inserm.fr/actualites/Pages/detail.aspx?news_id=301

https://anr.fr/fr/detail/call/appel-a-projets-ra-covid-19/

mercredi 25 novembre 2020

DIM ELICIT: Special Call SARS-CoV-2


 

The DIM ELICIT would like to support projects developing innovative technologies and methods regarding the analysis, diagnosis and / or treatment to fight SARS-CoV-2.

 

Any research team from the region Ile de France can apply with a project linked to the infectious agent SARS-CoV-2, and in accordance with the DIM ELICIT’s goals, positioning and thematic axes.

 

In the context of this call, the DIM ELICIT will fund each project:

- 15k€ for running and / or staff costs

and / or

- 30k€ of equipment

(66% max of total cost without VAT).

 

The projects submitted must target the acquisition of knowledge with a potential impact expected within 18 months following the funding.

 

This call will be open until the end of the crisis.

 

We will acknowledge the receipt of the applications within two days and try to give you a feedback on your eligibility within a week.

For more information and the application form, please see the link:
Special call for proposals - Fight SARS-CoV-2

https://dim-elicit.fr/appels-a-projets/

 

For any further question, do not hesitate to contact:
axel.bonetto@pasteur.fr or dim.elicit@pasteur.fr

lundi 30 novembre 2020

ARSEP: Working Visits


 

To facilitate exchanges between clinical centres and/or laboratories involved in MS. Travel may be within, to, or from France.

  • The training period can be up to 6 months.
  • Funding requests for up to 6.000 € to cover travel and accommodation are permitted.

Deadline: No deadline - throughout the year

https://www.arsep.org/fr/220-calls-for-proposals.html

https://www.arsep.org/library/media/other/Scientifique/Regulation-Working-visits-Travel-Grants-website.pdf

mardi 01 décembre 2020

ANR : Appel à projet générique, AAPG 2021


L'appel à projet générique de l'ANR permet de financer des projets de recherche individuelle portés par des jeunes chercheurs ou des jeunes chercheuses (JCJC), des projets de recherche collaborative, qu'ils soient nationaux (PRC) ou internationaux (PRCI) mais aussi des projets entre entités publiques et privées (PRCE).

Calendrier Prévisionnel AAPG 2021

Clôture du site de soumission Etape I : 1er Décembre 2020   

Notification des résultats de la première étape : Mars 2021      

Clôture du site de soumission Etp II : Fin Avril 2021       

Notification des premiers résultats des projets JCJC, PRC et PRCE : Fin Juillet 2021   

L’enregistrement des projets PRCI « Projet de recherche collaborative – international » pour lesquels l'ANR est Lead agency et hors Lead Agency doit nécessairement être effectué en phase 1 de l’AAPG 2021. Tous les projets PRCI enregistrés auprès de l’ANR en phase 1 sont qualifiés pour la phase 2 à condition d’éligibilité du projet enregistré. Cette mesure vise à assurer une gestion efficiente de la soumission et de la sélection des projets PRCI dans le cadre de l’AAPG 2021.

https://anr.fr/fr/detail/call/appel-a-projets-generique-aapg-2021/

jeudi 03 décembre 2020

The Wellcome Trust Foundation: Innovator Awards


 

These awards support researchers who are transforming great ideas into healthcare innovations that could have a significant impact on human health.

Level of funding: Up to £500,000, or up to £750,000 for multidisciplinary collaborations

Duration of funding: Usually up to 24 months, or up to 36 months for multidisciplinary collaborations

Key dates: You can apply online at any time. Shortlisting meetings happen every three months.

https://wellcome.org/grant-funding/schemes/innovator-awards

jeudi 03 décembre 2020

The American Parkinson Disease Association (APDA): Research Grants: Academic Year 2020-2021


Award:

One year grants up to a maximum of $75,000 will be awarded to research scientists (MD, MD/PhD, or PhD). The same investigator can reapply the following year to be considered for a second consecutive year of funding.

Goal:

APDA Research Grants are intended to support basic or applied research aimed at reducing the burden of Parkinson’s disease.  The APDA seeks to promote the entry of new investigators in to the field of Parkinson research, as well as to support important new ideas in the field worthy of investigation.

Eligibility:

All research scientists in the field of Parkinson’s research can apply, but the selection committee will more favorably consider researchers who are new to the field of Parkinson’s disease.

Deadline: 03/12/2020

Funding is not to be used for:

    Indirect costs.

    Institutional overhead.

    Salary for the principal investigator higher than $50,000.

    Travel expenses.

    Publication costs higher than $1,000.

    Equipment costs higher than $8,000.

https://www.apdaparkinson.org/research/research-opportunities/grants/

https://www.apdaparkinson.org/research/

vendredi 04 décembre 2020

AAP DREES-ONS : Le suicide et sa prévention 2020


Dans le cadre des travaux de l’Observatoire national du suicide (ONS) dont elle assure le secrétariat général, la Direction de la recherche, des études, de l’évaluation et des statistiques (DREES) lance un appel à projets de recherche sur les conduites suicidaires, ciblé sur certaines thématiques identifiées comme prioritaires par les membres de l’Observatoire pour leur faible couverture par des travaux de recherche ou leur actualité (pandémie de Covid-19).

Les projets attendus doivent relever des sciences humaines et sociales (sociologie, économie, démographie, gestion, sciences politiques, droit, histoire, sciences de la gestion, psychologie, etc.), de la biostatistique ou de l’épidémiologie. Des projets en psychiatrie sont également attendus mais, ils devront impérativement associer des équipes en sciences humaines et sociales et la partie du projet faisant appel aux SHS devra y être significativement développée et pertinente. 

 

Trois axes sont proposés :

-          Axe 1 : Spécificités des conduites suicidaires dans les départements et régions d’outre-mer (DROM) et les collectivités d’outre-mer (COM) français

-          Axe 2 : Dynamiques des conduites suicidaires chez les personnes âgées

-          Axe 3 : Pandémie de Covid-19 et conduites suicidaires

 

Le montant total alloué au financement de recherches est de 500 000 euros. En conséquence, chaque projet ne devra pas dépasser 100 000 euros. La sélection des projets sera assurée par un conseil scientifique indépendant. Elle tiendra compte du souhait de la DREES de répartir ses financements entre les trois axes.

 

Les projets sont attendus avant le 4 décembre 2020 à 12h (l’envoi électronique faisant foi).

Pour en savoir plus, téléchargez l’appel à projets de recherche, le dossier de réponse et l’annexe financière à l’adresse suivante :

https://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/recherche/appels-a-projets-de-recherche/article/le-suicide-et-sa-prevention

lundi 07 décembre 2020

American Brain Tumor Association (ABTA): Discovery Grants


 

Discovery Grants are one-year, $50,000 grants for high risk, high impact research with the potential to change current diagnostic or treatment models.

LOI Due: early December

Application Due: Mid-to-Late March

Discovery research projects are pre-screened by Letter of Intent (LOI), typically open in early November with LOIs due in December of every calendar year. Invitations and instructions to submit a full proposal are extended by email in February, with applications due in March.

https://www.abta.org/discovery-grants/

mercredi 09 décembre 2020

Funding opportunities from International Foundations


On this page discover the funding opportunities of international foundations according to your activity topics

 

Below the exel version

mercredi 09 décembre 2020

NIH Funding Opportunities


NIH Funding Opportunities (Foreign Institutions are eligible to apply) / Financements NIH ouverts aux institutions non-US

Ensemble d'appels d'offres ouverts aux institutions non-US, on this page, a set of calls for proposals that are open to non-US institutions

jeudi 10 décembre 2020

Financial support to the organization of scientific events


 

 

More information : please download the document

vendredi 01 janvier 2021

European Brain Research Area consortium (EBRA): Call for clusters



The EBRA consortium is launching a Call for Clusters to promote co-operation and exchange between brain research projects and networks, and thus enable or enhance international collaboration and the emergence of development of clusters in all areas of brain research.

A cluster is understood as an association of research projects that can be directed towards basic research, clinical research and/or methodological approaches under a common topic, and disease and/or thematic area.

The individual members of a cluster application should be complementary.

The cluster formation should lead to a step-wise change in the landscape of that research area and should demonstrate a clear added-value in the collaboration/cooperation over individual projects including, but not limited to, sharing of resources (models, databases, diagnostics etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies, etc.

The EBRA call for cluster is an open call until 1 January 2021.

Deadlines

1 June 2019
1 January 2020
1 June 2020
1 January 2021

More information: https://www.ebra.eu/Call4Clusters/

lundi 01 février 2021

The Focused Ultrasound Foundation


 

We fund high risk or clinically based investigator-initiated projects through the External Awards Program. We also fund projects in high-priority applications of FUS through the Brain Program, Cancer Immunotherapy Program, and Veterinary Program, including both invited and investigator-initiated projects.

Brain program: It is the ultimate goal of the Foundation's Brain Program to see focused ultrasound become a standard of care for the treatment of a range of neurological disorders, including movement disorders, brain tumors, epilepsy and stroke.

 

The External Awards Program provides funding for investigator-initiated clinical, preclinical, and early-stage research projects through a competitive peer-reviewed application process.

 

The program has two tracks:

* The Pre-Clinical Track is geared primarily towards preclinical studies and research projects that target a particular clinical indication or organ. It is meant to fund research that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years.

 

*The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated.

 

**Additionally, the External Awards Program accepts abstracts for Clinical Trial funding requests. The abstract form for Clinical Trials is linked in the Materials section below. Funding for clinical trials is not limited to $100,000 and one year.

 

Funding: one-year awards totaling approximately $100,000

The Pre-Clinical Track typically does not fund large capital purchases, cannot fund overhead or institutional expenses, and will not fund the development of new focused ultrasound equipment

 

Application Process

Step 1: A one-page Research Abstract must be submitted at least two weeks prior to the program’s quarterly application deadlines (Feb. 1, May 1, Aug. 1, and Nov. 1).

Step 2: The Foundation will invite full Research Proposals from authors of approved Research Abstracts.

Funding decisions are returned to the applicant approximately three months after their application deadline.

 

https://fusfoundation.org/for-researchers/external-research-awards-program/apply-for-funding

https://fusfoundation.org/for-researchers/external-research-awards-program

 

Questions?

Please contact Matt Eames, PhD, Director of External Research, at meames@fusfoundation.org.

 

 

mercredi 17 mars 2021

Innovative Medicines Intiative IMI2 23rd Call, Topic 3


 A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases (Topic code: IMI2-2020-23-03)

The Innovative Medicines Initiative is a jointly fund

 A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases (Topic code: IMI2-2020-23-03)

The Innovative Medicines Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Indicative budget:

    From EFPIA companies and IMI2 Associated Partners: EUR 47 360 000

    From the IMI2 JU: EUR 47 790 000

Key dates and deadlines:

    Draft topic texts published: 6 April 2020

    Publication date: 23 June 2020

    Stage 1 submission start date: 23 June 2020

    Stage 1 submission deadline: 29 September 2020 (17:00 Brussels time)

    Stage 2 submission deadline: 17 March 2021 (17:00 Brussels time)

 

Objectives in the scope of this topic:

  1. Create a set of agreed principles to enable sharing and access to data and samples, taking into consideration all the established legal and ethical research standards and principles (e.g. General Data Protection Regulation (GDPR), legal, intellectual property (IP), ethical, regulatory, societal issues) and their practical implementation.

  2. Establish a network that can house high quality data and samples, which could have federated and centralised elements. This must build on existing ongoing and relevant cohorts (see objective 4). The overall solution has to be interoperable (e.g. with other global data platforms), scalable and suitable for a broad variety of both data types (including digital), and samples, from public and private (e.g. proprietary clinical trials) sources, whether they be part of the consortium or provided from external donors. Activities related to building a biorepository or data management and sharing platform from scratch are out of scope for this topic. Instead, these must build upon existing resources (including ongoing longitudinal cohorts or studies), knowledge and infrastructures to deliver a novel solution able for seamlessly incorporating existing retrospective samples and data with prospective samples and data collections.

  3. Establish fair and transparent governance and processes specifically to enable sharing and access to data and samples.

  4. Test the above with the defined case studies and apply the learnings to fine-tune processes and use the outcomes to grow the platform. Case studies need to include (but are not limited to) the amyloid-tau-neurodegeneration (ATN) system (in cohorts with early Alzheimer’s disease) and the complement pathway (in Parkinson’s disease). Applicants have to include the well substantiated description of:
  • cohorts with early Alzheimer’s disease, which will allow the evaluation of the ATN system, comparing more complex and expensive markers like cerebrospinal fluid amyloid β (Aβ) & tau, amyloid-positron emission tomography (PET) and magnetic resonance imaging (MRI) with potential liquid biopsy (blood, saliva,..) markers as alternate biomarkers and;
  • cohorts with Parkinson’s disease to investigate the impact/relation of the complement system on diagnosis, severity and progression. This should be especially in light of new classes of minimally invasive neurodegenerative disease biomarkers (e.g. autoantibodies, DNA methylation, exosomes) and sample matrices (e.g. saliva).
  1. This platform must be a self-sustainable entity by the end of the project.

 More information: IMI2_Call23_CallText

https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-23

ed partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Indicative budget:

    From EFPIA companies and IMI2 Associated Partners: EUR 47 360 000

    From the IMI2 JU: EUR 47 790 000

Key dates and deadlines:

    Draft topic texts published: 6 April 2020

    Publication date: 23 June 2020

    Stage 1 submission start date: 23 June 2020

    Stage 1 submission deadline: 29 September 2020 (17:00 Brussels time)

    Stage 2 submission deadline: 17 March 2021 (17:00 Brussels time)

 

Objectives in the scope of this topic:

  1. Create a set of agreed principles to enable sharing and access to data and samples, taking into consideration all the established legal and ethical research standards and principles (e.g. General Data Protection Regulation (GDPR), legal, intellectual property (IP), ethical, regulatory, societal issues) and their practical implementation.

  2. Establish a network that can house high quality data and samples, which could have federated and centralised elements. This must build on existing ongoing and relevant cohorts (see objective 4). The overall solution has to be interoperable (e.g. with other global data platforms), scalable and suitable for a broad variety of both data types (including digital), and samples, from public and private (e.g. proprietary clinical trials) sources, whether they be part of the consortium or provided from external donors. Activities related to building a biorepository or data management and sharing platform from scratch are out of scope for this topic. Instead, these must build upon existing resources (including ongoing longitudinal cohorts or studies), knowledge and infrastructures to deliver a novel solution able for seamlessly incorporating existing retrospective samples and data with prospective samples and data collections.

  3. Establish fair and transparent governance and processes specifically to enable sharing and access to data and samples.

  4. Test the above with the defined case studies and apply the learnings to fine-tune processes and use the outcomes to grow the platform. Case studies need to include (but are not limited to) the amyloid-tau-neurodegeneration (ATN) system (in cohorts with early Alzheimer’s disease) and the complement pathway (in Parkinson’s disease). Applicants have to include the well substantiated description of:
  • cohorts with early Alzheimer’s disease, which will allow the evaluation of the ATN system, comparing more complex and expensive markers like cerebrospinal fluid amyloid β (Aβ) & tau, amyloid-positron emission tomography (PET) and magnetic resonance imaging (MRI) with potential liquid biopsy (blood, saliva,..) markers as alternate biomarkers and;
  • cohorts with Parkinson’s disease to investigate the impact/relation of the complement system on diagnosis, severity and progression. This should be especially in light of new classes of minimally invasive neurodegenerative disease biomarkers (e.g. autoantibodies, DNA methylation, exosomes) and sample matrices (e.g. saliva).
  1. This platform must be a self-sustainable entity by the end of the project.

 More information: IMI2_Call23_CallText

https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-23